Research
Hormonal
Pre-diabetes (Impaired Fasting Glucose and Impaired Glucose Tolerance) is associated with a twofold higher risk of cardiovascular events compared to normoglycemic subjects, driven by insulin resistance and clustering of risk factors.
If you have pre-diabetes, your risk of a heart event is already double that of someone with normal blood sugar. You should address insulin resistance and lifestyle factors immediately, rather than waiting for a diabetes diagnosis.
GoodSupportsHIGH confidence
Several studies show that subjects with impaired glucose tolerance (IGT... ) or impaired fasting glucose (IFG... ) have about twofold higher risk for CVD events than normoglycemic subjects.
Why this rating
Supported by multiple prospective cohort studies (Whitehall, DECODE, meta-analysis of 20 studies).
Source
Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms
Markku Laakso · Diabetes Care · 2010
DOI 10.2337/dc09-0749
narrative_reviewCited 304×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes acts as a coronary heart disease (CHD) equivalent, conferring a risk of myocardial infarction in diabetic patients without prior history that is equal to or greater than that of nondiabetic patients with prior myocardial infarction.Good
- Insulin resistance is a primary driver of cardiovascular disease in Type 2 Diabetes, often outweighing the direct impact of hyperglycemia on coronary heart disease risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →